Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: taxikid who wrote (820)	6/12/1997 12:20:00 AM
From: John Metcalf	of 6136

No, taxikid, I mean hyperglyemia. In any event, this investigation will not effect usage of protease inhibitors. This is from the news story (fair use claimed): WASHINGTON (Dow Jones)--The Food and Drug Administration issued a warning to doctors and patients that the breakthrough class of AIDS drugs, protease inhibitors, may cause elevated blood sugar and even diabetes in HIV patients. The FDA said 83 cases were reported of new or exacerbated diabetes mellitus and hyperglycemia, or increased blood sugar levels, in HIV-infected patients taking one of protease-inhibitors.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next